SCHEMBL95008

SCHEMBL95008

[CH2]c1ccc(C(=O)NCc2ccccc2Cl)cc1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.73
KMT2A Q03164 3/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 2/20 0.59
MAPT P10636 1/20 0.59
TP53 P04637 1/20 0.56
KDM4E B2RXH2 1/20 0.56
HIF1A Q16665 1/20 0.55
POLB P06746 1/20 0.55
ALDH1A1 P00352 2/20 0.54
CASP6 P55212 1/20 0.54
EPHX2 P34913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912570 0.87 SMN1; SMN2 (0.82) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL14531874 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL3590191 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL13947384 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL28649262 0.82 SMN1; SMN2 (0.69) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL3034646 0.82 SMN1; SMN2 (0.83) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL1568246 0.81 SMN1; SMN2 (0.68) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL28654120 0.79 SMN1; SMN2 (0.68) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL2305929 0.78 L3MBTL1 (0.63) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL94368 0.78 HDAC1 (0.77) LMNAMAPTKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB SMN1; SMN2 3998/4885KMT2A 1059/4885NPC1 2361/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 SMN1; SMN2 3084/4885KMT2A 2732/4885NPC1 2922/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 SMN1; SMN2 3084/4885KMT2A 2732/4885NPC1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.